FDA's Generic Drug Workload, Productivity Beating Budget Estimates
Executive Summary
ANDA submissions and approvals for FY 2017 likely to be higher than agency estimates, but FDA also predicts improved median approval time.
You may also be interested in...
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.
US FDA's Drug Shortage Effort Questioned By GAO
GAO's 'high risk' report lowers FDA grade for its drug shortage action plans, saying efforts have not been sustained.